Response to: “DOACs for Left Ventricular Thrombus: Persistent Equipoise Despite New Observational and Randomized Data”

This publication has 11 references indexed in Scilit:

• RIVAWAR Trial Commentary
  JACC: Advances, 2025
• Comparison of direct oral anticoagulants and vitamin K antagonists in the treatment of left ventricular thrombi: a retrospective cohort study
  Research and Practice in Thrombosis and Haemostasis, 2025
• Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction
  JACC: Advances, 2025
• Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update
  Thrombosis Journal, 2024
• Trial sequential analysis of efficacy and safety of direct oral anticoagulants and vitamin K antagonists against left ventricular thrombus
  Scientific Reports, 2023
• Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi—Insights from a Swiss Multicenter Registry
  The American Journal of Cardiology, 2023
• Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial)
  JACC, 2021
• Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus
  Annals of Pharmacotherapy, 2020
• The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction
  European Heart Journal - Cardiovascular Pharmacotherapy, 2020
• Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi
  JAMA Cardiology, 2020